These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28578659)

  • 21. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.
    Cuyàs E; Fernández-Arroyo S; Corominas-Faja B; Rodríguez-Gallego E; Bosch-Barrera J; Martin-Castillo B; De Llorens R; Joven J; Menendez JA
    Oncotarget; 2015 May; 6(14):12279-96. PubMed ID: 25980580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
    Johannessen TA; Mukherjee J; Viswanath P; Ohba S; Ronen SM; Bjerkvig R; Pieper RO
    Mol Cancer Res; 2016 Oct; 14(10):976-983. PubMed ID: 27430238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas.
    Hujber Z; Horváth G; Petővári G; Krencz I; Dankó T; Mészáros K; Rajnai H; Szoboszlai N; Leenders WPJ; Jeney A; Tretter L; Sebestyén A
    J Exp Clin Cancer Res; 2018 Nov; 37(1):271. PubMed ID: 30404651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.
    Kopinja J; Sevilla RS; Levitan D; Dai D; Vanko A; Spooner E; Ware C; Forget R; Hu K; Kral A; Spacciapoli P; Kennan R; Jayaraman L; Pucci V; Perera S; Zhang W; Fischer C; Lam MH
    Sci Rep; 2017 Oct; 7(1):13853. PubMed ID: 29062039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutant IDH1 is required for IDH1 mutated tumor cell growth.
    Jin G; Pirozzi CJ; Chen LH; Lopez GY; Duncan CG; Feng J; Spasojevic I; Bigner DD; He Y; Yan H
    Oncotarget; 2012 Aug; 3(8):774-82. PubMed ID: 22885298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
    Nagy N; Hajdu M; Márk Á; Király PA; Tóth M; Dankó T; Csóka M; Sebestyén A
    Tumour Biol; 2016 Oct; 37(10):13695-13704. PubMed ID: 27473087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant
    Mazor T; Chesnelong C; Pankov A; Jalbert LE; Hong C; Hayes J; Smirnov IV; Marshall R; Souza CF; Shen Y; Viswanath P; Noushmehr H; Ronen SM; Jones SJM; Marra MA; Cairncross JG; Perry A; Nelson SJ; Chang SM; Bollen AW; Molinaro AM; Bengtsson H; Olshen AB; Weiss S; Phillips JJ; Luchman HA; Costello JF
    Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10743-10748. PubMed ID: 28916733
    [No Abstract]   [Full Text] [Related]  

  • 28. Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations.
    Berger RS; Ellmann L; Reinders J; Kreutz M; Stempfl T; Oefner PJ; Dettmer K
    Sci Rep; 2019 May; 9(1):7436. PubMed ID: 31092874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis.
    Wang TX; Liang JY; Zhang C; Xiong Y; Guan KL; Yuan HX
    Cell Death Dis; 2019 Oct; 10(10):755. PubMed ID: 31591388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
    Chaturvedi A; Herbst L; Pusch S; Klett L; Goparaju R; Stichel D; Kaulfuss S; Panknin O; Zimmermann K; Toschi L; Neuhaus R; Haegebarth A; Rehwinkel H; Hess-Stumpp H; Bauser M; Bochtler T; Struys EA; Sharma A; Bakkali A; Geffers R; Araujo-Cruz MM; Thol F; Gabdoulline R; Ganser A; Ho AD; von Deimling A; Rippe K; Heuser M; Krämer A
    Leukemia; 2017 Oct; 31(10):2020-2028. PubMed ID: 28232670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.
    Reitman ZJ; Duncan CG; Poteet E; Winters A; Yan LJ; Gooden DM; Spasojevic I; Boros LG; Yang SH; Yan H
    J Biol Chem; 2014 Aug; 289(34):23318-28. PubMed ID: 24986863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.
    Izquierdo-Garcia JL; Viswanath P; Eriksson P; Cai L; Radoul M; Chaumeil MM; Blough M; Luchman HA; Weiss S; Cairncross JG; Phillips JJ; Pieper RO; Ronen SM
    Cancer Res; 2015 Aug; 75(15):2999-3009. PubMed ID: 26045167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced
    Li T; Cox CD; Ozer BH; Nguyen NT; Nguyen HN; Lai TJ; Li S; Liu F; Kornblum HI; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
    Mol Cancer Res; 2018 Jun; 16(6):947-960. PubMed ID: 29545476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo.
    Jia P; Wu Y; Du H; Yang L; Zhang Z; Ma T; Li S; Yuan S; Lu L; Zha X
    Eur J Pharm Sci; 2019 Dec; 140():105072. PubMed ID: 31518680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.
    Elhammali A; Ippolito JE; Collins L; Crowley J; Marasa J; Piwnica-Worms D
    Cancer Discov; 2014 Jul; 4(7):828-39. PubMed ID: 24740997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
    Bunse L; Pusch S; Bunse T; Sahm F; Sanghvi K; Friedrich M; Alansary D; Sonner JK; Green E; Deumelandt K; Kilian M; Neftel C; Uhlig S; Kessler T; von Landenberg A; Berghoff AS; Marsh K; Steadman M; Zhu D; Nicolay B; Wiestler B; Breckwoldt MO; Al-Ali R; Karcher-Bausch S; Bozza M; Oezen I; Kramer M; Meyer J; Habel A; Eisel J; Poschet G; Weller M; Preusser M; Nadji-Ohl M; Thon N; Burger MC; Harter PN; Ratliff M; Harbottle R; Benner A; Schrimpf D; Okun J; Herold-Mende C; Turcan S; Kaulfuss S; Hess-Stumpp H; Bieback K; Cahill DP; Plate KH; Hänggi D; Dorsch M; Suvà ML; Niemeyer BA; von Deimling A; Wick W; Platten M
    Nat Med; 2018 Aug; 24(8):1192-1203. PubMed ID: 29988124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IDH1 mutation promotes proliferation and migration of glioma cells via EMT induction.
    Lu J; Li D; Zeng Y; Wang H; Feng W; Qi S; Yu L
    J BUON; 2019; 24(6):2458-2464. PubMed ID: 31983120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
    Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
    Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
    Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
    Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
    Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
    PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.